John Hiscott "Oncolytic Virus Immunotherapies for Cancer" - 17 marzo 2016 ore 13.00

 John Hiscott, Direttore del Laboratorio Pasteur, Istituto Pasteur – Fondazione Cenci Bolognetti, Roma


Oncolytic Virus Immunotherapies for Cancer


Oncolytic virotherapy is an immunotherapeutic strategy that contributes to tumor eradication via direct tumor cell killing, blockage of tumor vascularization, and priming of an adaptive immune response that targets the tumor. This seminar will describe studies demonstrating the efficacy of oncolytic VSV in combination with small molecule compounds in prostate cancer and chronic lymphocytic leukemia. We will also provide an overview of the status of clinical trials in this emerging field.